Skip to main content

 

The Biosafety Advisory Council (BAC) is one of the two pillars (with the Service Biosafety and Biotechnology - SBB) of the scientific evaluation system that has been set up in Belgium to advise the Federal and Regional competent authorities about the biosafety of activities involving genetically modified organisms (GMOs) and/or pathogens.
 
The Council is composed of 12 effective and 12 substitute members designated by the different Regional and Federal competent authorities. It is assisted in its scientific work by external experts from academic institutions and by the SBB. The secretariat of the Council is ensured by the SBB.


The Council advises the authorities for all regulatory dossiers related to the deliberate release of GMOs in the environment or the placing on the market of GMOs and GMO-based products. The Council can be consulted by the Regions for contained activities involving GMOs and/or pathogens (i.e. activities taking place in laboratories, greenhouses, animal husbandries, production plants or hospital rooms).

Latest news

Advice on dossier B/BE/21/BVW​​​​7: Phase 1 clinical trial (SCS Boehringer Ingelheim Ltd.) involving a GM Vesicular Stomatitis Virus (VSV) for treatment of advanced cancer (solid tumors)
Advice on application EFSA-GMO-NL-2018-150 (genetically modified maize DP4114 x MON810 x MIR604 x NK603) from Pioneer intended for import and processing, food and feed
Advice on dossier B/BE/21/BVW​​​​5: Phase 3 clinical trial (Sarepta Therapeutics) involving a GM Adeno Associated Virus (AAV) for treatment of Duchenne Muscular Dystrophy
Advice on dossier B/BE/21/BVW​​​​8: Phase 3 clinical trial (MeiraGTx UK II Limited) involving a recombinant, replication-incompetent, adeno-associated virus (AAV) viral vector for treatment of X-linked Retinitis Pigmentosa
Advice on dossier B/BE/22/V3​: Field trial (VIB) involving GM maize with modified growth characteristics
Advice on dossier B/BE/22/V2​: Field trial (VIB) involving GM maize with improved digestibility
Advice on dossier B/BE/22/V1​: Field trial (VIB) involving GM maize with increased resistance against environmental stress
Advice on dossier B/BE/21/BVW​​​​6: Phase 2 clinical trial (GlaxoSmithKline Biologicals SA) involving a GM vaccinia virus Ankara vector for treatment of chronic Hepatitis B
Advice on dossier B/BE/21/BVW​​​​4: Phase 1b clinical trial (AMAL Therapeutics) to assess the safety, tolerability and the anti-tumor effect of a candidate viral vaccine in patients with stage IV Colorectal cancer
Advice on application EFSA-GMO-NL-2019-164 (genetically modified maize NK603 x T25 x DAS-40278-9) from Pioneer intended for import and processing, food and feed